ArticlePLoS computational biology2021
Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways.
Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 71 citations in OpenAlex.
- A unified framework combining linear and 3D molecular features for robust drug-protein interaction prediction.Cell reports methods · 2026Article
- Pathogenic KRAS variants disrupt structure and dynamics: Insights from integrated computational analyses.PloS one · 2026Article
- Reconciling multiple connectivity-based systems biology methods for drug repurposing.Briefings in bioinformatics · 2025Review
- Oleanolic Acid Restores Drug Sensitivity in Sorafenib-resistant Hepatocellular Carcinoma: Evidence fromJournal of clinical and translational hepatology · 2025Article
- Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma.International journal of molecular sciences · 2024Article
- ENCAP: Computational prediction of tumor T cell antigens with ensemble classifiers and diverse sequence features.PloS one · 2024Article
- Naringenin prevents non-alcoholic steatohepatitis by modulating the host metabolome and intestinal microbiome in MCD diet-fed mice.Food science & nutrition · 2023Article
- A First Computational Frame for Recognizing Heparin-Binding Protein.Diagnostics (Basel, Switzerland) · 2023Article
- Recall DNA methylation levels at low coverage sites using a CNN model in WGBS.PLoS computational biology · 2023Article
- Bitter-RF: A random forest machine model for recognizing bitter peptides.Frontiers in medicine · 2023Article
- A drug repurposing method based on inhibition effect on gene regulatory network.Computational and structural biotechnology journal · 2023Article
- Prediction of apoptosis protein subcellular location based on amphiphilic pseudo amino acid composition.Frontiers in genetics · 2023Article
- Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by inducing autophagic apoptosis through endoplasmic reticulum stress.BMC complementary medicine and therapies · 2022Article
- IBPred: A sequence-based predictor for identifying ion binding protein in phage.Computational and structural biotechnology journal · 2022Article
- Identification ofComputational and mathematical methods in medicine · 2022Article
- The Characterization of Structure and Prediction for Aquaporin in Tumour Progression by Machine Learning.Frontiers in cell and developmental biology · 2022Article
- Identifying and Classifying Enhancers by Dinucleotide-Based Auto-Cross Covariance and Attention-Based Bi-LSTM.Computational and mathematical methods in medicine · 2022Article
- ZNF165 Is Involved in the Regulation of Immune Microenvironment and Promoting the Proliferation and Migration of Hepatocellular Carcinoma by AhR/CYP1A1.Journal of immunology research · 2022Article
- Ensemble Learning-Based Feature Selection for Phage Protein Prediction.Frontiers in microbiology · 2022Article
- KRAS is a prognostic biomarker associated with diagnosis and treatment in multiple cancers.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a significant health problem worldwide with poor prognosis. Drug repositioning represents a profitable strategy to accelerate drug discovery in the treatment of HCC. In this study, we developed a new approach for predicting therapeutic drugs for HCC based on tissue-specific pathways and identified three newly predicted drugs that are likely to be therapeutic drugs for the treatment of HCC. We validated these predicted drugs by analyzing their overlapping drug indications reported in PubMed literature. By using the cancer cell line data in the database, we constructed a Connectivity Map (CMap) profile similarity analysis and KEGG enrichment analysis on their related genes. By experimental validation, we found securinine and ajmaline significantly inhibited cell viability of HCC cells and induced apoptosis. Among them, securinine has lower toxicity to normal liver cell line, which is worthy of further research. Our results suggested that the proposed approach was effective and accurate for discovering novel therapeutic options for HCC. This method also could be used to indicate unmarked drug-disease associations in the Comparative Toxicogenomics Database. Meanwhile, our method could also be applied to predict the potential drugs for other types of tumors by changing the database.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.